MDR’s hidden toll: why small medtechs are exiting the EU market

MDR was supposed to raise the floor on patient safety and create a harmonised single market. To be fair, the theory is sound. In practice this means a much higher bar of clinical evidence, heavier technical documentation (Annex II), and ongoing post-market obligations (Annex XIV) that scale poorly for small teams. I’ve watched otherwise-viable Class IIa and IIb manufacturers in Switzerland and the EU quietly stop selling into Europe because the compliance bill didn’t add up. Genau — it’s not glamorous, but it matters.

Why SMEs feel the squeeze

The cost drivers are familiar but cumulative:

• Notified-body availability and scrutiny: fewer NB slots, more detailed questions on clinical evaluation (Article 61) and equivalence claims, and divergent interpretation between bodies.
• Clinical evidence expectations: PMCF plans and active follow-up are no longer optional add-ons; they’re core to demonstrating continued safety and performance (Annex XIV).
• Technical documentation depth: Annex II requires traceable, up-to-date dossiers. “Good enough” slide decks from five years ago won’t pass.
• Ongoing surveillance: PSURs, vigilance reporting, trend analysis — these are recurring costs, not one-offs.
• Process and tool investment: an eQMS with proper traceability, change impact mapping, and CAPA workflows isn’t cheap to implement well.

Individually some of these are manageable. Together they morph into a strategic decision point: invest heavily now and accept lower margin, or withdraw from the market.

What I’ve seen in practice

I work on CE-marking submissions and post-market surveillance for Class IIa/IIb devices. Practical patterns I’ve observed:

• Companies underestimate the PMCF runway. A PMCF study that can be accepted by a notified body often needs a protocol similar in rigour to a clinical investigation — and monitoring it requires resources (data collection, statisticians, CRAs).
• Equivalence claims are a frequent rejection point. Notified bodies increasingly ask for direct clinical data rather than reliance on legacy products. That’s fine for a large firm with multiple legacy lines — not for a start-up.
• Technical Files get returned for insufficient traceability across risk management, clinical data, and instructions for use. Annex II’s expectation that you can show “why this document changed” and “who approved it” is not trivial if you’re using spreadsheets and email.
• EUDAMED/UDI pain persists. To be fair, many manufacturers still wrestle with UDI and EUDAMED submission loops; it’s time and admin that small teams hate.

So ist das halt — the regulatory system is working towards safety, but the administrative and evidence costs favour larger players.

Practical steps that actually reduce cost (not just marketing claims)

If you’re a two- to ten-person RA/QA team with the EU market on the line, here are pragmatic moves that have worked for peers I advise:

• Prioritise portfolio rationalisation first. Ask which SKUs deliver the margin that justifies MDR rework. Narrow scope and do fewer things well.
• Make the Technical File modular. Structure files so shared modules (e.g., manufacturing, risk management templates) serve multiple products; that reduces duplication during audits.
• Invest in traceability where it matters. A basic, reliable live-reactive traceability map (linking risk controls → IFU → clinical claims → test reports) saves weeks during NB queries. If you must choose where to spend, choose traceability over flashy dashboards.
• Treat PMCF pragmatically: focus on high-yield activities — targeted registries, routinely collected real-world data, and focused questionnaires — rather than broad, costly prospective studies when suitable. Annex XIV permits proportionate approaches; document your rationale clearly.
• Outsource smartly. Regulatory consultants are expensive, but a short-term contract to get your clinical evaluation and PMCF plan into a notified-body-ready state can be cheaper than repeated NB rejections.
• Use automation for recurrent tasks: automated CAPAs and CAPA-driven risk assessment workflows reduce human error and decrease time-to-closure. Controlled assistance and AI-assisted draft suggested actions can speed writing CAPA records — but ensure reviewability and traceability.
• Negotiate NB scope up front. Clarify what the NB expects for equivalence and clinical data before submission. Get written confirmation of critical expectations where possible.

What regulators and notified bodies could change (brief wishlist)

To keep SMEs in the market, systemic changes are needed; a few practical adjustments would help:

• Harmonised, transparent guidance on equivalence and minimum PMCF expectations. Divergent NB interpretations are a real cost multiplier.
• Proportionate pathways for legacy, low-risk devices with long safety histories — a clearer, faster route for demonstrably low-risk products.
• Support for shared, open registries that reduce the burden of individual PMCF studies.

I’m cynical here but not without cause: many of these changes are policy-level and slow. Meanwhile SMEs have to make financial decisions now.

Conclusion

I still believe patient safety must come first. That does not contradict the observation that current MDR implementation financially disadvantages small manufacturers. The regulatory system can and should be fairer in practice by offering proportionality and clearer expectations. In the meantime, SMEs need lean documentation, modular files, and better eQMS traceability — and they need to treat PMCF and clinical evaluation as ongoing product costs, not one-off boxes to tick.

How have you balanced the costs of MDR compliance with staying in the EU market — which specific approaches actually saved your company time or money?